Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy

Chaithanya Ganji, Batoul Farran

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Pancreatic cancer (PC) is an aggressive disease characterized by high mortality. Diagnosis at advanced stage, resistance, and recurrence are major hurdles for PC therapy and contribute to poor survival rate. Mutations in tumor-promoting kinases and epigenetic dysregulation in tumor suppressor genes are hallmarks of PC and can be used for diagnosis and therapy. In this review, we highlight dysregulated genes associated with epigenetic mechanisms, including DNA methylation and histone acetylation, involved in PC progression and resistance. We also explore epigenetic drugs currently in clinical trials. Combining epigenetic drugs and targeted therapies might represent a promising approach for PC.

Original languageEnglish (US)
Pages (from-to)1404-1410
Number of pages7
JournalDrug Discovery Today
Volume27
Issue number5
DOIs
StatePublished - May 2022
Externally publishedYes

Keywords

  • DNA methylation
  • DNMTi
  • Epigenetics
  • HDACi
  • Histone acetylation
  • Pancreatic cancer

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy'. Together they form a unique fingerprint.

Cite this